IT1274350B - Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 - Google Patents

Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Info

Publication number
IT1274350B
IT1274350B ITRM940794A ITRM940794A IT1274350B IT 1274350 B IT1274350 B IT 1274350B IT RM940794 A ITRM940794 A IT RM940794A IT RM940794 A ITRM940794 A IT RM940794A IT 1274350 B IT1274350 B IT 1274350B
Authority
IT
Italy
Prior art keywords
antagonists
consist
interface
soluble forms
interleuchina
Prior art date
Application number
ITRM940794A
Other languages
English (en)
Inventor
Gennaro Ciliberto
Carlo Toniatti
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Priority to ITRM940794A priority Critical patent/IT1274350B/it
Publication of ITRM940794A0 publication Critical patent/ITRM940794A0/it
Priority to CN95191457A priority patent/CN1139933A/zh
Priority to EP95940401A priority patent/EP0742794A1/en
Priority to JP8517466A priority patent/JPH09503232A/ja
Priority to PCT/IT1995/000208 priority patent/WO1996017869A2/en
Priority to CA002177837A priority patent/CA2177837A1/en
Priority to AU41866/96A priority patent/AU4186696A/en
Publication of ITRM940794A1 publication Critical patent/ITRM940794A1/it
Application granted granted Critical
Publication of IT1274350B publication Critical patent/IT1274350B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Si tratta di antagonisti di interleuchina-6, caratterizzati dal fatto di consistere di forme solubili del recettore ? di IL-6 umana (shIL-6R?) contenenti una o più mutazioni nell'interfaccia che si lega a gp 130. In una variante preferita, le mutazioni sono presenti in una posizione scelta dal gruppo comprendente Ala 228, Asn 230, His 280 e Asp 281. Questi antagonisti possono essere usati come agenti capaci di prevenire e curare malattie causate da una anormale attività di IL-6.La figura 4 mostra l'attività antagonistica del mutante Ala228Asp/Asn230Asp/His280Ser/Asp281Val in confronto alle proprietà agonistiche di shIL-6R? di tipo selvatico. Questo antagonista può essere usato per la preparazione di farmaci per la prevenzione, il controllo e la cura delle malattie dovute ad una anormale bioattività di IL-6.
ITRM940794A 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 IT1274350B (it)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
CN95191457A CN1139933A (zh) 1994-12-06 1995-12-05 由在GP130结合介面突变的白细胞介素-6(IL-6)受体α的可溶形式组成的IL-6拮抗剂
EP95940401A EP0742794A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
JP8517466A JPH09503232A (ja) 1994-12-06 1995-12-05 ＧＰ１３０結合界面で突然変異したインターロイキン−６（ＩＬ−６）受容体αの可溶性型であるＩＬ−６アンタゴニスト
PCT/IT1995/000208 WO1996017869A2 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
CA002177837A CA2177837A1 (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
AU41866/96A AU4186696A (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Publications (3)

Publication Number Publication Date
ITRM940794A0 ITRM940794A0 (it) 1994-12-06
ITRM940794A1 ITRM940794A1 (it) 1996-06-06
IT1274350B true IT1274350B (it) 1997-07-17

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Country Status (7)

Country Link
EP (1) EP0742794A1 (it)
JP (1) JPH09503232A (it)
CN (1) CN1139933A (it)
AU (1) AU4186696A (it)
CA (1) CA2177837A1 (it)
IT (1) IT1274350B (it)
WO (1) WO1996017869A2 (it)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
CA2230949C (en) * 1995-09-28 2009-11-17 Judith Chebath Synthetic peptides that inhibit il-6 activity
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
EP2322216A1 (en) 1997-03-21 2011-05-18 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
ES2276525T3 (es) 1998-08-24 2007-06-16 Chugai Seiyaku Kabushiki Kaisha Preventivos o remedios para la pancreatitis que contienen anticuerpos anti-receptor il-6 como ingrediente activo.
ATE372126T1 (de) * 1998-11-05 2007-09-15 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
AU7078200A (en) 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
WO2004073741A1 (ja) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６アンタゴニストを含有する脊髄損傷治療剤
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
MXPA06003768A (es) 2003-10-17 2006-06-23 Chugai Pharmaceutical Co Ltd Agente terapeutico para el mesotelioma.
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
CA2728243C (en) 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
EP2898896A1 (en) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
CN112566650A (zh) * 2018-06-21 2021-03-26 沙塔克实验室有限公司 异二聚体蛋白及其用途
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR
CN110133241B (zh) * 2019-05-21 2022-05-27 中国食品药品检定研究院 一种测定重组人可溶性gp130-Fc融合蛋白生物学活性的新方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3363463B2 (ja) * 1991-10-02 2003-01-08 忠三 岸本 Ｉｌ−６レセプター誘導体

Also Published As

Publication number Publication date
JPH09503232A (ja) 1997-03-31
EP0742794A1 (en) 1996-11-20
WO1996017869A2 (en) 1996-06-13
CA2177837A1 (en) 1996-06-07
CN1139933A (zh) 1997-01-08
AU4186696A (en) 1996-06-26
WO1996017869A3 (en) 1996-08-29
ITRM940794A0 (it) 1994-12-06
ITRM940794A1 (it) 1996-06-06

Similar Documents

Publication Publication Date Title
IT1274350B (it) Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
Forss et al. From amalgam to composite: selection of restorative materials and restoration longevity in Finland
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
MXPA04001187A (es) Receptores de interleucina-1 en el tratamiento de enfermedades.
WO2000064441A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
MXPA04003666A (es) Uso de flibanserina para tratamiento de trastornos sexuales.
MXPA04011612A (es) Uso oftalmologico de roflumilasto para el tratamiento de enfermedades del ojo.
TW200507849A (en) Methods for treating interleukin-6 related diseases
WO1999017755A3 (en) Medicaments
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
PL404315A1 (pl) Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku
CA2439879A1 (en) C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
PL377715A1 (pl) Antagoniści CCR1 do leczenia między innymi demielizacyjnej choroby zapalnej
EP1228758A4 (en) PROHYLACTIC AND THERAPEUTIC AGENTS FOR INFLAMMABLE COLON DISEASES
RU98101907A (ru) Терапевтические агенты и аутоимунные заболевания
HUP0401805A2 (hu) Pulmonális betegségek kezelésére szolgáló vegyületek
IL162482A (en) Use of the il6 – r / il – 6 chimera in the manufacture of a drug for the treatment of neuronal loss
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
WO2002046221A3 (en) Human protein differentially expressed in alzheimer's disease's brain
MXPA02006511A (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido.
HUP0001526A2 (hu) Nukleozidok alkalmazása citokinekkel kapcsolatos megbetegedések kezelésére szolgáló gyógyszerkészítmények előállítására és gyógyszerkészítmények
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
CA2274063A1 (en) Substituted pyrimidine compounds and their use
GB9930077D0 (en) Medicaments

Legal Events

Date Code Title Description
0001 Granted